Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06600321 · ClinicalTrials.gov registry record · Phase 1
A Study to Evaluate ALN-BCAT in Patients With Hepatocellular Carcinoma
A Phase 1 study of Advanced Hepatocellular Carcinoma and Metastatic Hepatocellular Carcinoma, sponsored by Alnylam Pharmaceuticals.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 158
- Enrollment target
- 20
- Study locations
NCT06600321: Recruiting Phase 1 study of Advanced Hepatocellular Carcinoma and Metastatic Hepatocellular Carcinoma, sponsored by Alnylam Pharmaceuticals.
NCT06600321 is a Phase 1 study of Advanced Hepatocellular Carcinoma and Metastatic Hepatocellular Carcinoma that is actively recruiting participants, run by Alnylam Pharmaceuticals. The registered enrollment target is 158 participants, above the 78-participant average among 16 other Advanced Hepatocellular Carcinoma trials with a reported enrollment target (103% higher). The trial reports 20 study locations across 13 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06600321, a Phase 1 study of Advanced Hepatocellular Carcinoma and Metastatic Hepatocellular Carcinoma, is actively recruiting participants, sponsored by Alnylam Pharmaceuticals.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 158 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of the dose escalation part of the study is to characterize the safety and tolerability of ALN-BCAT as monotherapy and in combination with pembrolizumab; and to determine the recommended dose(s) for expansion (RDFE) of ALN-BCAT as monotherapy and in combination with pembrolizumab. The purpose of the dose expansion part of the of the study is to evaluate the antitumor activity of ALN-BCAT as monotherapy and in combination with pembrolizumab; to characterize the safety and tolerability of ALN-BCAT as monotherapy and in combination with pembrolizumab.
Conditions Studied
Interventions
- DRUG Pembrolizumab
- DRUG ALN-BCAT
Study Locations (20)
Other
- Clinical Trial Site - Milan
- Clinical Trial Site - Rozzano
- Clinical Trial Site - Verona
- Clinical Trial Site - Busan
Texas
- Clinical Trial Site - Dallas
- Clinical Trial Site - Houston
- Clinical Trial Site - San Antonio
California
- Clinical Trial Site - La Jolla
- Clinical Trial Site - Los Angeles
New York
- Clinical Trial Site - New York
- Clinical Trial Site - New York
Arizona
- Clinical Trial Site - Phoenix
Florida
- Clinical Trial Site - Jacksonville
Georgia
- Clinical Trial Site - Atlanta
Illinois
- Clinical Trial Site - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 158 participants |
| Start Date | 2024-12-30 |
| Est. Completion | 2027-10-31 |
| Phase | Phase 1 |
What NCT06600321 shows while recruiting
NCT06600321 is an interventional study that assigns participants to a tested intervention. The registered 158 participants enrollment target is mid-sized for trials with a published cap, above the 78-participant average among 16 other Advanced Hepatocellular Carcinoma trials with a reported enrollment target (103% higher).
The record links to 2 conditions, with Advanced Hepatocellular Carcinoma appearing as the primary indexed condition, and to 2 interventions - of which Pembrolizumab is the first listed.
NCT06600321 names 20 study sites across 13 states, led by Other, Texas, California.
Frequently Asked Questions
What is clinical trial NCT06600321 about?
NCT06600321 is a clinical study titled "A Study to Evaluate ALN-BCAT in Patients With Hepatocellular Carcinoma". The purpose of the dose escalation part of the study is to characterize the safety and tolerability of ALN-BCAT as monotherapy and in combination with pembrolizumab; and to determine the recommended dose(s) for expansion (RDFE) of ALN-BCAT as monotherapy and in combination with pembrolizumab. The pu...
What is the current status of trial NCT06600321?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 158 participants. The study started on 2024-12-30. Estimated completion is 2027-10-31.
What conditions does trial NCT06600321 study?
This clinical trial studies the following conditions: Advanced Hepatocellular Carcinoma, Metastatic Hepatocellular Carcinoma.
What interventions are being tested in trial NCT06600321?
The interventions under investigation include: Pembrolizumab (DRUG), ALN-BCAT (DRUG).
Who is sponsoring clinical trial NCT06600321?
This trial is sponsored by Alnylam Pharmaceuticals, which has 49 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06600321 being conducted?
This trial has 20 study locations across Arizona, California, Florida, Georgia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced Hepatocellular Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06600321's enrollment target sits among peer trials
158 4th of 16 higher than 13 of 16 other Advanced Hepatocellular Carcinoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Advanced Hepatocellular Carcinoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Testing the Addition of an Anti-cancer Drug, Sapanisertib, to the Usual Chemotherapy Treatment (Cabozantinib) in Metastatic Liver Cell Cancer With a Change in Genes for the Protein β-Catenin, The SAPHIRE Trial
RECRUITING · Phase 1
-
AU409 for the Treatment of Advanced Primary Liver Cancers or Solid Tumor With Liver Metastatic Disease
RECRUITING · Phase 1
-
A Study of Tegavivint (BC2059) in Patients With Advanced Hepatocellular Carcinoma
RECRUITING · Phase 1
-
Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib or With Pembrolizumab and Nab-Paclitaxel in Patients With Advanced Solid Tumors Involving the Abdomen or Thorax
RECRUITING · Phase 1
-
Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV
ACTIVE NOT RECRUITING · Phase 1
-
Siliphos in Advanced Hepatocellular Carcinoma
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04486833 · 158 participants · Phase 1
Quaratusugene Ozeplasmid (Reqorsa) and Osimertinib in Patients With Advanced Lung Cancer Who Progressed on Osimertinib
- NCT04697966 · 158 participants · NA
Mechanisms and Predictors of Change in App-Based Mindfulness Training for Adolescents
- NCT04969835 · 158 participants · Phase 1
A Study Evaluating the Safety, Pharmacokinetics and Early Efficacy of AVA6000 in Solid Tumours
- NCT05230732 · 158 participants · NA
Neuromodulation of Inflammation and Endothelial Function
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI